Stocks have consolidated over the past week and now appear to be positioned at a critical technical crossroads. The S&P 500 is wedged between the 61.8% Fibonacci retracement level and its 200-day moving average.
Let’s get into the two stocks I’m looking at this summer – and take a quick peek at Luke Lango’s special portfolio and how these seven stocks all represent even more reasons to stay invested this summer...
The past week has been a whirlwind of political and business news. From President Donald Trump's personal calls to CEOs to an attempted assassination of a Cabinet nominee, there's a lot to unpack. Let's dive into the top stories of the week.
Powell avoided naming stagflation but outlined its ingredients—rising inflation and unemployment—and linked these risks to tariff policies. The Fed is clearly signaling that tariff relief is essential for monetary easing.
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance of $2.19 billion at the midpoint came in 2% above analysts’ estimates. Its GAAP profit of $3.67 per share was 20.8% above analysts’ consensus estimates.
The highlights for the week ahead include what is expected to be little-changed US CPI readings, Japan and the UK's first estimates of Q1 25 GDP, the UK and Australia's latest employment report, and a 50 bp rate cut by the central bank of Mexico.
